Literature DB >> 18364546

Cross-fire doses from beta-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics.

S A Enger1, T Hartman, J Carlsson, H Lundqvist.   

Abstract

A mathematical model based upon histological findings of cell cluster distributions in primary breast cancers and lymph node metastases was developed. The model is unique because it accounts for tumor cell cluster formations within both primary tumors and metastases. The importance of inter-cell cluster cross-fire radiation dose for beta-emitting radionuclides of different energies was studied. The cell clusters were simulated as spheres with 15, 25 and 50 microm radii having a homogeneous radioactivity distribution. The self-dose as well as the dose distribution around the spheres was calculated for seven radionuclides, (90)Y, (188)Re, (32)P, (186)Re, (159)Gd, (131)I and (177)Lu using the GEANT4 Monte Carlo code. Generally, the self-dose was decreasing with increasing energy of the emitted beta particles. An exception was (188)Re which, compared to (32)P, had higher beta energy as well as higher self-dose. This was due to the higher emission of conversion and Auger electrons in the (188)Re-decay. When the cell clusters had a mean distance that was shorter than the maximum range of beta-particles, then the inter-cluster cross-fire radiation contributed significantly to the absorbed dose. Thus, high-energy beta-particles may, in spite of a low self-dose to single clusters, still be favorable to use due to the contribution of inter-cluster cross-fire radiation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18364546     DOI: 10.1088/0031-9155/53/7/007

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  13 in total

1.  The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts.

Authors:  Carol A Nelson; Michael T Azure; Christopher T Adams; Kurt R Zinn
Journal:  J Nucl Med       Date:  2014-10-30       Impact factor: 10.057

2.  Relative Biological Effectiveness (RBE) of (131)I Radiation Relative to (60)Co Gamma Rays.

Authors:  Ali Neshasteh-Riz; Ali Mahmoud Pashazadeh; Seyed Rabie Mahdavi
Journal:  Cell J       Date:  2013-08-24       Impact factor: 2.479

3.  The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.

Authors:  Alexander H Staudacher; Fares Al-Ejeh; Cara K Fraser; Jocelyn M Darby; David M Roder; Andrew Ruszkiewicz; Jim Manavis; Michael P Brown
Journal:  EJNMMI Res       Date:  2014-01-04       Impact factor: 3.138

4.  DNA damage of glioblastoma multiform cells induced by Beta radiation of iodine-131 in the presence or absence of topotecan: a picogreen and colonogenic assay.

Authors:  Nazila Eyvazzadeh; Ali Neshasteh-Riz; Seyed Rabee Mahdavi
Journal:  Cell J       Date:  2015-04-08       Impact factor: 2.479

5.  In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.

Authors:  Ho Sze Chan; Erik de Blois; Alfred Morgenstern; Frank Bruchertseifer; Marion de Jong; Wouter Breeman; Mark Konijnenberg
Journal:  PLoS One       Date:  2017-07-21       Impact factor: 3.240

6.  Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.

Authors:  Nadia Falzone; Nicole L Ackerman; Liset de la Fuente Rosales; Mario A Bernal; Xiaoxuan Liu; Sarah Gja Peeters; Manuel Sarmiento Soto; Aurélien Corroyer-Dulmont; Myriam Bernaudin; Elisa Grimoin; Omar Touzani; Nicola R Sibson; Katherine A Vallis
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.600

7.  Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations.

Authors:  Klaudia Siwowska; Patrycja Guzik; Katharina A Domnanich; Josep M Monné Rodríguez; Peter Bernhardt; Bernard Ponsard; Roger Hasler; Francesca Borgna; Roger Schibli; Ulli Köster; Nicholas P van der Meulen; Cristina Müller
Journal:  Pharmaceutics       Date:  2019-08-20       Impact factor: 6.321

Review 8.  Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.

Authors:  Jiaxian Chen; Lin Qi; Yongxiang Tang; Guyu Tang; Yu Gan; Yi Cai
Journal:  Front Cell Dev Biol       Date:  2022-08-12

9.  Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code.

Authors:  Milad Peer-Firozjaei; Mohammad Ali Tajik-Mansoury; Raheb Ghorbani; Mahdi Mazinani
Journal:  J Biomed Phys Eng       Date:  2021-06-01

10.  Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy.

Authors:  Maria Larsson; Peter Bernhardt; Johanna B Svensson; Bo Wängberg; Håkan Ahlman; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2012-09-24       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.